仙琚制药(002332) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders increased by 32.54% to CNY 117,116,082.56 for the reporting period[10] - Operating revenue for the period was CNY 909,294,905.00, reflecting a 2.02% increase year-on-year[10] - Basic earnings per share rose by 30.00% to CNY 0.13 for the reporting period[10] - The net profit after deducting non-recurring gains and losses increased by 38.20% to CNY 119,868,861.00 for the reporting period[10] - The company's net profit for the current period is CNY 130,796,187.47, an increase of 34.3% compared to CNY 97,431,768.58 in the previous period[57] - Total operating revenue for the current period reached ¥2,769,045,484.21, an increase of 4.49% compared to ¥2,650,144,267.02 in the previous period[71] - Net profit for the current period was ¥326,346,375.05, representing a 42% increase from ¥230,038,441.95 in the previous period[74] - The total profit for the current period is CNY 158,424,772.69, an increase of 25.6% from CNY 126,102,283.59 in the previous period[57] - The company reported a total profit of ¥404,461,470.76, an increase from ¥305,352,572.43, reflecting a growth of 32.4%[74] Assets and Liabilities - Total assets increased by 7.31% to CNY 5,840,943,609.42 compared to the end of the previous year[10] - The company's total assets amounted to ¥3,812,850,626.01, compared to ¥3,668,116,819.21 in the previous year, marking an increase of about 3.9%[53] - The total liabilities decreased slightly to ¥1,246,286,286.96 from ¥1,257,599,287.85, indicating a reduction of approximately 0.9%[50] - The total liabilities were $2.73 billion, with current liabilities at $1.61 billion and non-current liabilities at $1.13 billion[109] - The company reported a total liability of CNY 1,257,599,287.85, with current liabilities at CNY 1,016,165,734.86 and non-current liabilities at CNY 241,433,552.99[118] Cash Flow - The net cash flow from operating activities decreased by 64.12% to CNY 54,259,401.20 compared to the same period last year[10] - Cash inflow from operating activities reached ¥2,546,877,983.17, up from ¥2,298,575,381.00, showing a growth of approximately 10.8%[87] - Net cash flow from operating activities was ¥402,960,442.22, compared to ¥237,880,404.02 in the previous period, representing a substantial increase[88] - The company received tax refunds of ¥16,312,640.08, significantly higher than ¥113,881.24 in the previous period, indicating improved cash management[90] - The company reported a net increase in cash and cash equivalents of ¥140,735,827.24, compared to ¥175,279,525.61 in the previous period, indicating a decrease in cash generation[93] Research and Development - Research and development expenses increased by 31.79% year-on-year, an increase of 26.49 million yuan, mainly due to increased R&D spending[23] - Research and development expenses increased significantly to CNY 38,580,047.98, compared to CNY 19,783,317.76 in the previous period, marking a rise of 94.8%[65] - Research and development expenses increased to ¥109,797,711.66, up from ¥83,312,630.38, marking a growth of 31.93%[71] Equity and Shareholder Information - The total net assets attributable to shareholders increased by 7.40% to CNY 2,826,441,545.49 compared to the end of the previous year[10] - The total equity attributable to shareholders reached ¥2,566,564,339.05, up from ¥2,410,517,531.36, reflecting an increase of approximately 6.5%[53] - The owner's equity totaled $2.71 billion, with the equity attributable to shareholders amounting to $2.63 billion[109] - The company reported a significant increase in undistributed profits, which rose to ¥603,492,581.57 from ¥447,445,773.88, reflecting a growth of approximately 34.9%[53] Compliance and Adjustments - The company adjusted its financial statements to reflect the new financial instrument standards, impacting the classification of certain assets[100] - The report indicates a focus on compliance with new financial regulations without retrospective adjustments affecting previous financial indicators[118] - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[119]